Immunotherapy in Acute Myeloid Leukemia: Where We Stand
In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, growth and recurrence has gained increasing interes...
Main Authors: | Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian, Antonio Curti |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.656218/full |
Similar Items
-
Acute myeloid leukemia: current progress and future directions
by: Hagop Kantarjian, et al.
Published: (2021-02-01) -
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01) -
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
by: Bachar Samra, et al.
Published: (2020-06-01) -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
by: Nicholas J. Short, et al.
Published: (2019-02-01) -
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)